Nautilus
Delivering a high-throughput, low-cost platform for analyzing and quantifying the human proteome.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 -27.3x EV/EBITDA | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 -27.3x EV/EBITDA | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 110 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (1662 %) | (876 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (1831 %) | (875 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Nautilus Biotechnology operates in the biotechnology sector, focusing on proteomics, which is the large-scale study of proteins. The company has developed an advanced platform designed to accelerate the drug development process by providing researchers with deep insights into the roles of drug targets in health and disease. This platform aims to make it easier to prioritize drug targets with high potential for clinical success, thereby reducing inefficiencies and costs associated with traditional drug discovery methods. Nautilus Biotechnology serves pharmaceutical companies, research institutions, and biotech firms, offering them a tool to enhance their research capabilities and improve clinical outcomes. The business model is primarily B2B (business-to-business), generating revenue through the sale of its proteomics platform and related services. By unlocking the proteome, Nautilus aims to fuel breakthroughs in basic biology, medicine, and biotechnology, ultimately impacting global health positively.
Keywords: proteomics, drug discovery, biotechnology, clinical success, pharmaceutical, research, platform, health, innovation, efficiency.
